National Comprehensive Cancer Network
3025 Chemical Road, Suite 100
About National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of 28 leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, efficient, and accessible cancer care so patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system.
By defining and advancing high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers around the world. World-renowned experts from NCCN Member Institutions diagnose and treat patients with a broad spectrum of cancers and are recognized for dealing with complex, aggressive, or rare cancers. NCCN Member Institutions pioneered the concept of the multidisciplinary team approach to patient care and conduct innovative research that contributes significantly to understanding, diagnosing, and treating cancer. NCCN programs offer access to expert physicians, superior treatment, and quality and safety initiatives that continuously improve the effectiveness and efficiency of cancer care globally.
NCCN 20th Anniversary Video - Improving Cancer Care Together
January 31, 2015 marked the 20th anniversary of the National Comprehensive Cancer Network; originally announced as an alliance of 13 leading cancer centers in 1995, NCCN has grown to a network of 26 academic cancer centers devoted to patient care, research, and education.
Featuring past and present leadership, this video describes the groundbreaking accomplishments of NCCN over the past two decades that have improved the quality, effectiveness, and efficiency of cancer care so that patients can live better lives.
104 articles with National Comprehensive Cancer Network
NCCN Oncology Research Program and Puma Biotechnology, Inc. Collaborate to Study Neratinib in Various Cancers
The National Comprehensive Cancer Network ® ( NCCN ® ) Oncology Research Program ( ORP ) today announced plans to evaluate neratinib, a type of tyrosine kinase inhibitor (TKI) that works as a dual
The NCCN Virtual Nursing Forum and Annual Congress: Hematologic Malignancies ( #NCCNhem20 ) will provide the latest evidence and expert consensus on emerging practices and debates in blood cancer treatment, online Thursday, October 8, 2020 – Saturday, October 10, 2020 .
Virtual #NCCNPolicy Summit features congressional staffers and representatives from CMS, COA, BIO, discussing legislative and regulatory approaches for reducing health care costs.
Gold standard clinical practice guidelines in oncology updated and translated for greater global accessibility; free online at NCCN.org/global.
Leading Cancer Treatment Recommendations from NCCN Now Available in French, German, Italian, Portuguese, Russian, and Spanish
Gold standard clinical practice guidelines in oncology translated for greater global accessibility; free online at NCCN.org/global.
The NCCN Virtual Nursing Forum and Annual Congress: Hematologic Malignancies ( #NCCNhem2020 ) will provide the latest evidence and expert consensus on emerging practices and debates in blood cancer treatment, online October 8-10 . PLYMOUTH MEETING, Pa. , Aug. 27, 2020 /PRNewswire/ -- The National Comprehensive Cancer Network ® ( NCCN ® ) has announced this year's NCC
National Comprehensive Cancer Network(R) Adds Monjuvi(R) (tafasitamab-cxix) to its Clinical Practice Guidelines in Oncology for B-cell Lymphomas
MorphoSys AG and Incyte announced that Monjuvi®, a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, has been included in the latest National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology for B-cell Lymphomas.
NCCN Oncology Research Program Announces Projects Selected for Funding to Study Futibatinib in Tumors with Aberrant FGFR Expression, in Collaboration with Taiho Oncology
Researchers from NCCN Member Institutions will evaluate futibatinib in order to improve treatment for cancers with FGFR aberrations.
National Comprehensive Cancer Network issues Request for Proposals (RFP) for projects that develop and validate enduring approaches to improve the safe, effective, and efficient adoption of biosimilars in oncology. [15-July-2020] PLYMOUTH MEETING, Pa. , July 15, 2020 /PRNewswire/ -- The National Comprehensive Cancer Network ® ( NCCN ® ) Oncology Research Program ( O
The NCCN Distress Thermometer enables discussion and treatment of distress as part of routine care for people with cancer. This free resource is now translated into 46 languages for global accessibility.
Newly-completed series of patient guidelines from National Comprehensive Cancer Network shares expert advice with patients and caregivers on treatment and prevention for most common head and neck cancers.
NCCN Foundation Awards Leading Young Investigators Advancing Cancer Research for Adults and Children
National Comprehensive Cancer Network Foundation's annual Young Investigator Awards granted to top early-career researchers from leading cancer centers seeking tomorrow's cures
The NCCN 2020 Annual Conference providing the latest updates on cancer treatment recommendations was initially postponed due to COVID-19.
New information from NCCN, ASCO, ASH, CDC, FDA, and others seeks to provide clear guidance on how to optimally manage cancer-related pain without exacerbating the ongoing opioid crisis--published jointly in the Journal of the National Comprehensive Cancer Network and JCO Oncology Practice.
National Comprehensive Cancer Network Announces Addition of UCLA Jonsson Comprehensive Cancer Center and UT Southwestern Simmons Comprehensive Cancer Center
Los Angeles- and Dallas-based cancer centers join alliance of leading medical institutions that create guidelines which define optimal cancer management in the U.S. and globally
NCCN Updates Professional Guidelines Recommending Biomarker Testing for Unfavorable Intermediate and High-Risk Patients with Prostate CancerProlaris One of Only Two Prognostic Tests Recommended for Expanded Indications
Myriad Genetics, Inc. announced that the National Comprehensive Cancer Network updated its professional guidelines for prostate cancer to recommend biomarker-based testing for men with unfavorable intermediate and high-risk disease.
National Comprehensive Cancer Network Releases Recommendations for Standardizing Quality Measurements in Oncology
NCCN Quality and Outcomes Committee's endorsements of impactful and feasible quality and outcomes measures offer opportunities to advance the quality of cancer care in America
National Comprehensive Cancer Network Postpones 2020 Annual Conference, Citing Precautions against Potential Patient Exposure to COVID-19
Annual gathering of leading oncology professionals to discuss latest cancer research and guidelines postponed out of concern for vulnerable populations.
NCCN Oncology Research Program to oversee projects to improve patient care and outcomes in advanced lung cancer
NCCN celebrates 25th anniversary year; shares updates from oncology experts on leading-edge cancer management practices during NCCN 2020 Annual Conference in Orlando #NCCN2020